Skeletal responses to romosozumab after 12 months of denosumab

ABSTRACT Romosozumab, a monoclonal anti‐sclerostin antibody that has the dual effect of increasing bone formation and decreasing bone resorption, reduces fracture risk within 12 months. In a post hoc, exploratory analysis, we evaluated the effects of romosozumab after 12 months of denosumab in postm...

詳細記述

書誌詳細

主要な著者:	Michael R. McClung, Michael A. Bolognese, Jacques P. Brown, Jean‐Yves Reginster, Bente L. Langdahl, Yifei Shi, Jen Timoshanko, Cesar Libanati, Arkadi Chines, Mary K. Oates
フォーマット:	Artigo
言語:	Inglês
出版事項:	Oxford University Press 2021-07-01
シリーズ:	JBMR Plus
主題:	ANABOLIC ANTIRESORPTIVE DENOSUMAB ROMOSOZUMAB TREATMENT SEQUENCE
オンライン･アクセス:	https://doi.org/10.1002/jbm4.10512
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!